John DiGiovanni

John DiGiovanni is an Investment Partner in the healthcare investment team at Arsenal Capital Partners, a leading private equity firm that specializes in investments in middle- market healthcare companies. Mr. DiGiovanni focuses on investments in provider services, healthcare technology, and direct care provision. He serves as a Board Director at Accumen, a technology-enabled provider of performance optimization for health systems, as well as Hopebridge, a leading provider of autism therapy services designed to meet the needs of children requiring behavioral diagnosis and applied behavioral analysis (ABA), occupational, feeding, and speech treatments in both home and school settings.

Previously, Mr. DiGiovanni spent ten years serving as a Principal for Baird Capital, working in Chicago, IL and London, UK, where he focused on investments into digital, software, and data-driven businesses in the healthcare industry. While at Baird, he served as a Board Director for several healthcare portfolio companies, including ReMed (traumatic brain injury rehabilitation), Prescient Healthcare Group (biopharmaceutical consultancy) and MERGE (digital marketing agency).

Prior to Baird, Mr. DiGiovanni worked in investment banking at Bank of America Merrill Lynch, focusing on mergers and acquisitions, restructurings and equity and debt offerings.

Mr. DiGiovanni currently serves as a Vice Chairman of the Board of Directors at Gilda’s Club, a New York City-based non-profit which offers free comprehensive cancer programs including support groups, educational lectures and workshops for those impacted by cancer. He has previously served as a Board Director for The Chicago Children’s Museum and The Cara Program, and also served as an Education Pioneers Fellow.

Mr. DiGiovanni holds graduate education degrees from Harvard University and Northwestern University, and a BA with Honors from Michigan State University.